Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA

By D. Haber, Victor E. Velculescu. Cancer Discovery, 2014

637 citations recorded by the source corpus.

The ability to study nonhematologic cancers through noninvasive sampling of blood is one of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven both by major technologic advances, including the isolation of intact cancer cells and the analysis of cancer cell–derived DNA from blood samples, and by the increasing application of molecularly driven therapeutics, which rely on such accurate and timely measurements of critical biomarkers. Moreover, the dramatic efficacy of these potent cancer therapies drives the selection for additional genetic changes as tumors acquire drug resistance, necessitating repeated sampling of cancer cells to adjust therapy in response to tumor evolution. Together, these advanced noninvasive diagnostic capabilities and their applications in guiding precision cancer therapies are poised to change the ways in which we select and monitor cancer treatments. Significance Recent advances in technologies to analyze circulating tumor cells and circulating tumor DNA are setting the stage for real-time, noninvasive monitoring of cancer and providing novel insights into cancer evolution, invasion, and metastasis.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/e34f3c2bd6c3fd20152e3a413fa1528b450080ed

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Nicholas McGranahan
2. Charles Swanton
3. R. DePinho

In Molecular Biology

1. Nicholas McGranahan
2. Charles Swanton
3. R. DePinho

In Oncology

1. Nicholas McGranahan
2. Charles Swanton
3. R. DePinho

Citations in the corpus

• AACR Project GENIE: Powering Precision Medicine through an International Consortium (2017, background): “In addition, analyses of circulating tumor DNA or circulating tumor cells from blood specimens or other bodily fluids (28) may be included to identify molecular changes in cancer genomes at the time of diagnosis or during therapy as these analyses become included in routine laboratory practice.”
• RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics (2015, neutral): “In order to overcome limitations of tissue acquisition, the use of blood-based liquid biopsies has been suggested (Alix-Panabie`res et al., 2012; Crowley et al., 2013; Haber and Velculescu, 2014).”
• Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. (2017, positive): “Serial sampling of tumor genomes from plasma and circulating tumor cells is now increasingly implemented in both clinical research settings to monitor cancer clonal evolution and drug resistance mechanisms over time (Haber and Velculescu, 2014) as well as the evolution of metastatic disease (Carreir”
• Genetics and biology of prostate cancer (2018, background): “…involving CTCs, cell-free tumor DNA, microRNAs, and microvesicles isolated from the blood, urine, saliva, pleural effusions, and cerebrospinal fluid (Alix-Panabieres et al. 2012; Alix-Panabieres and Pantel 2014; Haber and Velculescu 2014; Yap et al. 2014; Siravegna et al. 2017; Wan et al. 2017).”